Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Branding Part D: Big Changes for Biggest Plans

This article was originally published in RPM Report

Executive Summary

When it comes to Medicare Part D, the brand counts at least that’s what some of the biggest plans have concluded. From Humana/Walmart to CVS/Member Health, the drug benefit is increasingly a story of branding, both in the selling proposition to consumers and in the branding of certain plans as underperformers by CMS

You may also be interested in...



Medicare Rebates: Bigger is Better, But is Big Government Best?

An inspector General report takes the first public look at rebating under Medicare Par D.For Henry Waxman the message is that private negotiation isn't working to capture deep enough discounts. But the more important message for sponsors is that the report shows CMS remains firmly committed to the private sector drug insurance model.

Hostile Takeover

CVS Caremark’s acquisition of the MemberHealth Part D business brings with it a relationship with the National Community Pharmacy Association on the Community Care Rx plan. NCPA doesn’t think highly of its potential new business partner. Here are some recent press releases issued by the trade association.

Humana-Mart: The New Part D Plan Raises More Questions Than Answers

Walmart and Humana are offering an insurance plan that comes in at about half the price of the rest of the competition in the Part D market. Why are they doing it, how are they doing it, and what does it mean for drug manufacturers?

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS080779

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel